Skip to main content

NeuroSense Therapeutics Ltd.

NRSN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001875091

No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.

Other share classesNRSNW

Q2 2025 vs. Q1 2025

How the institutions holding NeuroSense Therapeutics Ltd. changed between Q1 2025 and Q2 2025.

All holders in Q2 2025All holders in Q1 2025

13F holders of NRSN: Q1 2025 compared with Q2 2025
MeasureQ1 2025Q2 2025Change
Holders1117+6
Shares194.9K510.0K+315.2K (+161.7%)
Value$180.8K$964.4K+$783.6K (+433.4%)

New holders (9)

Institutions that held NeuroSense Therapeutics Ltd. at the end of Q2 2025 but not at the end of Q1 2025.

Institutions new to NRSN in Q2 2025
InstitutionSharesValue% of portfolio
Citadel Advisors LLC149,243$282.1K0.00%
Yorkville Advisors Global, LP60,000$113.4K0.06%
Squarepoint Ops LLC49,925$94.4K0.00%
Jane Street Group, LLC28,689$54.2K0.00%
HRT Financial LP21,694$41.0K0.00%
Marshall Wace, LLP11,828$22.4K0.00%
Jones Financial Companies LLLP10,919$20.7K0.00%
BNP Paribas Arbitrage, SA6,800$12.9K0.00%
Total Investment Management Inc500$9450.00%

Sold out (3)

Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2025 and filed for Q2 2025 without it.

Institutions that sold out of NRSN in Q2 2025
InstitutionShares, Q1 2025Value, Q1 2025
XTX Topco Ltd33,706$31.0K
Two Sigma Securities, LLC14,705$13.7K
Warberg Asset Management LLC10,700$9.95K